_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Expands patient reach to remotest towns by furthering investment in GoApptiv
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla and Ethris partner for the development of mRNA-based therapies
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Strengthens investment in channels of the future to expand patient reach
Subscribe To Our Newsletter & Stay Updated
